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LETTER-PRELIMINARY REPORT/TECHNIQUE
Is Partial-ALPPS Safer Than ALPPS?
A Single-center Experience
Henrik Petrowsky, MD, FACS,∗ Georg Gyo¨ri, MD,∗ Michelle de Oliveira, MD, FACS,∗ Mickae¨l Lesurtel, MD, PhD,∗
and Pierre-Alain Clavien, MD, PhD, FACS†
T he recent introduction of associating liver partition and portalvein ligation for staged hepatectomy (ALPPS) into the clinical
practice of hepatobiliary surgery has offered a novel and promising
treatment strategy for patients with a variety of primarily nonre-
sectable hepatic tumors.1,2 Despite the great potential of ALPPS in
triggering rapid hypertrophy of parts of the liver, the main concern is
the safety of the procedure. For example, the reported mortality in the
initial series from Germany was 12%2 and 15% in a subsequent mul-
ticentric analysis,3 reaching even 27% in experienced hepatobiliary
centers.4 Such figures have triggered the search for better selection
criteria and/or technical modification enabling safer surgery.
A recently published analysis of the international ALPPS reg-
istry including 202 patients revealed an in-hospital mortality rate
of 9% and a severe complication (grade ≥3b)5 rate of 28%.6 The
risk analysis of this cohort suggested that older patients (>60 years
of age) and those with noncolorectal liver tumors had poorer
prognosis.6 To better understand the underlying mechanisms and as-
sociated harms, we have developed an experimental model of ALPPS
that showed that accelerated regeneration in ALPPS is not solely re-
lated to parenchymal transection and discontinuation of blood supply
between the 2 parts of the liver but mostly due to an “inflammatory-
like reaction” leading to enhanced hepatocyte growth.7 This finding
was substantiated by a similar effect on liver regeneration for portal
vein ligation associated with kidney, lung, or spleen injuries instead
of hepatic transection. Also, we observed in the experimental model
that partial (75%–80%) transection of the liver triggered a comparable
degree of regeneration of the future liver remnant (FLR) when com-
pared with complete transection. Aside with these novel experimental
findings, we have generated the hypothesis, from our early clinical ex-
perience, that complete transection of the parenchyma may enhance
postoperative liver injury, for example, by causing congestion of the
“deportalized” part of the liver. On the basis of our experimental
and clinical observations, we developed a new strategy, introduced
in 2013 at our institution, to switch from complete transection to a
well-defined partial transection (>50% of the transection surface).
The rationale behind this idea was our hypothesis that partial ALPPS
is safer and achieves similar rapid hypertrophy.
This report presents our experience with partial transection,
labeled as partial-ALPPS (both abbreviated as p-ALPPS), compared
with ALPPS looking at hypertrophy of the FLR and postoperative
outcome. We performed 24 ALPPS procedures in noncirrhotic and
noncholestatic patients without major extrahepatic surgery at stage 1
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or stage 2 during the period October 2012 to June 2014. Indications
for the procedures were colorectal liver metastases (n = 16), neu-
roendocrine tumors (n = 2), intrahepatic cholangiocarcinoma (n =
2), hepatocellular carcinoma (n = 1), hemangiopericytoma (n = 1),
and other secondary liver tumors (n = 2). Eighteen of the 24 pro-
cedures were classical ALPPS performed until early 2013 when we
switched to p-ALPPS (n = 6). Both ALPPS and p-ALPPS were per-
formed by the same surgeons at our institution and solely differed
in the degree of liver partition. Although liver transection was com-
plete in all ALPPS procedures (identical to our living related liver
transplantation procedures), it involved 50% to 80% of the complete
transection plane in the p-ALPPS cohort and was always performed
as an anterior approach. Portal vein ligation was performed routinely
in each case at stage 1, and intraoperative management and surgical
transection techniques were standardized in both groups. Our goal
was to transect at least 50% of the future transection plane at stage 1,
but the degree of partial transection was determined by anatomic out-
flow structures (hepatic veins), which we tried to preserve at stage 1
and/or by tumor(s) located within or near the future transection line,
which explained the different degree of partial transection ranging
from 50% to 80% in this series. Whereas 4 of the 6 patients with p-
ALPPS had simultaneous tumor-cleaning procedures of the FLR by
wedge resections and/or local ablation techniques using microwave
and/or irreversible electroporation (Nanoknife) at stage 1 surgery, 2
patients with p-ALPPS had not.
The p-ALPPS procedures included 3 right hemihepatectomies
(segments 5–8), 2 extended right hemihepatectomies (segments 4–8),
and 1 left trisectorectomy (segments 1–5 and 8) (Fig. 1).
The sex distributionwas similarwith a female-to-male percent-
age of 50%:50% in p-ALPPS and 44%:56% in ALPPS. The median
age of the p-ALPPS and ALPPS group was 59 years (range, 25–69
years) and 59 years (range, 33–76 years), respectively. The median
standardized FLR before stage 1 was comparable for both groups
(p-ALPPS 0.25 vs ALPPS 0.23). We observed a rapid hypertrophy
in p-ALPPS, with a median hypertrophy of 60% compared with 61%
hypertrophy in ALPPS within a median time of 7 days. Accordingly,
the kinetic growth after stage 1 procedure was 15% standardized
FLR increase per week for both groups. Even in the light of the fact
that other studies reported higher percent hypertrophy in ALPPS in
larger cohorts (79%–80%),2,6 the observed hypertrophy in p-ALPPS
seems remarkable and enabled a fast transition from stage 1 to stage 2
operation in our p-ALPPS series. The median time between stage 1
and stage 2 was 11 days (range, 7–21 days) in p-ALPPS and 9 days
(range, 7–69 days) in ALPPS. Despite the small sample size of our
case series, the data indicate that p-ALPPS triggers rapid hypertro-
phy, similar to ALPPS, allowing a fast completion of the 2-stage
hepatectomy.
We recorded zero in-hospital mortality in p-ALPPS, although
22% of the patients (4/18) died after the conventional ALPPS pro-
cedure. The 4 fatalities in the ALPPS group were cardiac failure in
1 patient and liver failure with subsequent multiorgan decompensa-
tion in 3 patients. Although no severe postoperative complications
(grade ≥3b) were observed after stage 1 procedure in p-ALPPS,
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FIGURE 1. A 61-year-old female patient with extensive bilobar colorectal liver metastases undergoing curative p-ALPPS procedure.
A, Magnetic resonance image shows extensive tumor before stage 1 operation. Only segments 6 and 7 are tumor free. B, The
patient underwent partial liver partition between the anterior and posterior right liver sectors with concomitant left portal vein
ligation and selective ligation of portal vein branches of the right anterior sector (segments 5 and 8). The line of partial partition
was marked with electrocautery after demarcation following selective clamping (arrows). C, Computed tomographic scan on
postoperative day 6 after stage 1 operation showing the partial partition line (arrows) and rapid hypertrophy of the FLR (segments
6 and 7). Stage 2 surgery was completed 3 weeks later as left trisectorectomy involving segments 1 to 5 and 8. D, Computed
tomographic scan 3 months after stage 2 procedure shows a well-recovered liver remnant after p-ALPPS.
6 of 18 patients (33%) experienced severe complications in the
ALPPS group after stage 1 procedure. After stage 2 operation, 6
patients (33%) developed severe complications in the ALPPS group
and 2 patients (33%) in the p-ALPPS group. The 2 patients in the
p-ALPPSgroup, however, developedwound-healing problems requir-
ing only surgical revision. The median comprehensive complication
index8,9 was higher in ALPPS for stage 1 (15 vs 0) and stage 2 (22
vs 15) and for both stages (38 vs 15) than that in p-ALPPS (Fig. 2).
These data indicate that p-ALPPS is associated not only with zero
mortality but also with a trend toward a more favorable postoperative
complication profile especially after stage 1 operation. The median
length of total intensive care unit stay after stage 1 and stage 2 sur-
gical procedures was 3.5 days for ALPPS and 2 days for p-ALPPS,
respectively.
In view of the ongoing and somewhat “passionate” debate
about this new challenging procedure, we felt that it is critical to re-
port on safer approaches achieving the same goals. This single-center
data suggest that p-ALPPS represents an attractive technical simpli-
fication, which, to the best of our knowledge, has not been reported
before. The impact of this modification has been encouraging in our
center leading to zero postoperative mortality and lower morbidity.
Whether such strategy may also be effective in a more extended use
of ALPPS, such as in cirrhotic patients or in the presence of perihilar
cholangiocarcinoma or gallbladder cancer, remains to be established.
The current data should, of course, be considered with caution
due to the nonrandomized, nonmatched study design and the relatively
FIGURE 2. In-hospital postoperative morbidity assessed by the
CCI. The CCI of each patient undergoing p-ALPPS (n = 6) or
ALPPS (n = 18) is presented as scatter plot with medians for
stage 1, stage 2, and stage 1 + 2 operations. CCI indicates
comprehensive complication index.
small number of patients. This single-center data must, however, be
reported and submitted to the experience of others. We speculate that
the partial liver partition approach is a safer operation than ALPPS.
Partial ALPPS induces a rapid hypertrophy, which, even if perhaps
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lower than ALPPS, is sufficient to enable the fast and beneficial
second-stage operation leading to complete resection. Because of the
very recent practice of ALPPS, and even more so, for p-ALPPS,
statements on the oncological outcome cannot be drawn yet. To vali-
date the present findings and to overcome the relatively small sample
size, an analysis of collected p-ALPPS cases in the registry should be
undertaken as the next step.
Finally, a shortcoming in this new area of liver surgery is the
lack of clear terminology. With the aim to facilitate the communica-
tion among clinicians regarding the complete (conventional) ALPPS
versus p-ALPPS, we propose to standardize the name of p-ALPPS as
“partial-ALPPS.”
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